ONCAlert | Upfront Therapy for mRCC

Tripathy Discusses a Study of Talazoparib in BRCA-Mutated Advanced Breast Cancer

Debu Tripathy, MD
Published Online: 7:26 PM, Tue June 6, 2017

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the phase II ABRAZO study of talazoparib (BMN-673) following platinum or multiple cytotoxic regimens in advanced breast cancer patients with germline BRCA 1/2 mutations during the 2017 ASCO Annual Meeting.

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.